In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
Health on MSN3d
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss DrugsIn response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
HealthDay on MSN3d
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for NowOn October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...
,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...
Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...
Britain is studying the use of Eli Lilly's weight loss drug, Tirzepatide, to address long-term sickness impacting its economy ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback